Acute Exacerbations of Chronic Functional Diarrhea

CONTROL OF ACUTE EXACERBATIONS OF CHRONIC FUNCTIONAL DIARRHEA

Bar graph. Reliable relief for patients with chronic functional diarrhea. Compares relief at day 2 and day 4 for Motofen versus placebo. Reference: 1.

	Patients
Patients with chronic functional diarrhea who achieved relief¹	Motofen (n of 24)	Placebo (n of 23)
Day 2, P value of less than 0.05 versus placebo	58%	26%
Day 4, difference not significant at 48 hours	57%	36%

More than half of the patients experienced statistically significant control of diarrhea by day 2 of treatment with Motofen. Control of diarrhea was consistently maintained at day 4 of treatment.¹

Click below to review the full poster on Motofen data

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Accidental overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Please click here for full Prescribing Information

REFERENCES: 1. Data on file, Sebela Pharmaceuticals. 2. Motofen [package insert]. Roswell, GA: Sebela Pharmaceuticals; August 2018. 3. Lomotil Tablets [package insert]. New York, NY: Pfizer Inc.; 2018.

Lomotil is a registered trademark of Pfizer Inc.

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Accidental overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Lomotil is a registered trademark of Pfizer Inc.